
CKM Syndrome: The Broad Health Risk Tying Heart, Kidney, and Metabolism
The American Heart Association coined CKM syndrome in 2023 to describe the overlap of cardiovascular, kidney, and metabolic diseases driven by excess weight, high blood pressure, and high blood sugar. It’s defined as a four‑stage continuum (Stage 0–Stage 4) with about 90% of Americans on the spectrum; prevention focuses on lifestyle changes (Mediterranean-style diet, physical activity, sleep, avoiding nicotine) and broad‑acting medications (GLP‑1s, SGLT2 inhibitors, nsMRAs) alongside traditional treatments like metformin, statins, and ACE inhibitors to slow progression and reduce hospitalizations. The overarching message is awareness and prevention, rather than overmedicalizing those at risk—including Stage 0 individuals who are at risk but not yet diseased.













